Imaging of hepatocellular carcinoma by computed tomography and magnetic resonance imaging: State of the art

Digestive Diseases

Volumn 27, Issue 2, 2009, Pages 114-124

  Zech, Christoph J ^a   Reiser, Maximilian F ^a   Herrmann, Karin A ^a  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

Author keywords

Computed tomography; Hepatocellular carcinoma; Liver cirrhosis; Magnetic resonance imaging; Regenerative nodule

Indexed keywords

ADULT; CANCER DIAGNOSIS; CELL DENSITY; CLINICAL ARTICLE; CLINICAL EVALUATION; COMPUTER ASSISTED TOMOGRAPHY; DIFFUSION WEIGHTED IMAGING; FEMALE; HUMAN; HUMAN TISSUE; KUPFFER CELL; LIVER CELL CARCINOMA; LIVER FUNCTION; MALE; MULTIDETECTOR COMPUTED TOMOGRAPHY; NEOVASCULARIZATION (PATHOLOGY); NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; RADIODIAGNOSIS; REVIEW;

CARCINOMA, HEPATOCELLULAR; HUMANS; LIVER NEOPLASMS; MAGNETIC RESONANCE IMAGING; TOMOGRAPHY, X-RAY COMPUTED;

EID: 67650932416     PISSN: 02572753     EISSN: None     Source Type: Journal    
DOI: 10.1159/000218343     Document Type: Review

References (66)

1. MacSween RNM, Burt A, Portmann B: Pathology of the Liver, ed 4. London, Churchill Livingstone, 2002
2. Ferrell LD, Crawford JM, Dhillon AP,Scheuer PJ, Nakanuma Y: Proposal for standardized criteria for the diagnosis of benign,borderline, and malignant hepatocellular lesions arising in chronic advanced liver disease. Am J Surg Pathol 1993;17:11131123.
3. International Working Party: Terminology of nodular hepatocellular lesions. Hepatology 1995;22:983993.
4. Matsui O: Imaging of multistep human he patocarcinogenesis by CT during intraarterial contrast injection. Intervirology 2004; 47:271276.
5. Hwang GJ, Kim MJ, Yoo HS, Lee JT: Nodular hepatocellular carcinomas: detection with arterial, portal, and delayedphase images at spiral CT. Radiology 1997;202:383388.
6. Schima W, Kulinna C, BaSsalamah A, Griinberger T: Multidetector computed to mography of the liver. Radiologe 2005; 45:1523.
7. Baron RL: Understanding and optimizing use of contrast material for CT of the liver. Am J Roentgenol 1994;163:323331.
8. Kawata S, Murakami T, Kim T, et al: Multide tector CT: diagnostic impact of slice thickness on detection of hypervascular hepatocellular carcinoma. Am J Roentgenol 2002;179:6166.
9. Haider MA, Amitai MM, Rappaport DC, et al: Multidetector row helical CT in preoperative assessment of small (< or = 1.5 cm) liver metastases: is thinner collimation better? Radiology 2002;225:137142.
10. Wedegartner U, Lorenzen M, Nagel HD, et al: Image quality of thin and thickslice MSCT reconstructions in lowcontrast objects (liver lesions) with equal doses. Rofo 2004;176:16761682.
11. Iannaccone R, Laghi A, Catalano C, et al: Hepatocellular carcinoma: role of unen hanced and delayedphase multidetector row helical CT in patients with cirrhosis. Radiology 2005;234:460467.
12. Bruix J, Sherman M: Management of hepa tocellular carcinoma. Practice Guidelines Committee, American Association for the Study of Liver Diseases. Hepatology 2005;42:12081236.
13. Bartolozzi C, Crocetti L, Lencioni R, Cioni D, Della Pina C, Campani D: Biliary and re ticuloendothelial impairment in hepatocar cinogenesis: the diagnostic role of tissue specific MR contrast media. Eur Radiol 2007;17:25192530.
14. Burrel M, Llovet JM, Ayuso C, et al: MRI angiography is superior to helical CT for detection of HCC prior to liver transplantation: an explant correlation. Hepatology 2003; 38:10341042.
15. Maetani YS, Ueda M, Haga H, et al: Hepatocellular carcinoma in patients undergoin livingdonor liver transplantation. Accuracy of multidetector computed tomography by viewing images on digital monitors. Intervi rology 2008;51(suppl 1):4651.
16. Kim SJ, Kim SH, Lee J, et al: Ferucarbotran enhanced 3.0T magnetic resonance imaging using parallel imaging technique compared with triplephase multidetector row computed tomography for the preoperative detection of hepatocellular carcinoma. J Comput Assist Tomogr 2008; 32: 379385.
17. 2weighted sequences using integrated parallel imaging: comparison of prospective motion correction and respiratory triggering. J Magn Reson Imaging 2004; 20:443450.
18. Zech CJ, Schoenberg SO, Herrmann KA, et al: Modern visualization of the liver with MRT. Current trends and future perspectives. Radiologe 2004;44:11601169.
19. Rofsky NM, Lee VS, Laub G, et al: Abdominal MR imaging with a volumetric interpolated breathhold examination. Radiology1999;212:876 884.
20. Matsui O, Kadoya M, Kameyama T, et al: Adenomatous hyperplastic nodules in the cirrhotic liver: differentiation from hepatocellular carcinoma with MR imaging. Radiology1989;173:123126.
21. Kadoya M, Matsui O, Takashima T, Nonomura A: Hepatocellular carcinoma: correlation of MR imaging and histopathologicfindings. Radiology 1992;183:819825.
22. Shinmura R, Matsui O, Kobayashi S, et alCirrhotic nodules: association between MR imaging signal intensity and intranodular blood supply. Radiology 2005;237:512519.
23. Hanna RF, Aguirre DA, Kased N, Emery SC,Peterson MR, Sirlin CB: Cirrhosisassociated hepatocellular nodules: correlation of his topathologic and MR imaging features. Radiographics 2008; 28: 747769.
24. Grazioli L, Olivetti L, Fugazzola C, et al: The pseudocapsule in hepatocellular carcinoma: correlation between dynamic MR imaging and pathology. Eur Radiol 1999;9:6267.
25. Onaya H, Itai Y: MR imaging of hepatocel lular carcinoma. Magn Reson Imaging Clin N Am 2000;8:757768.
26. Taouli B, Vilgrain V, Dumont E, Daire JL,Fan B, Menu Y: Evaluation of liver diffusion isotropy and characterization of focal hepatic lesions with two singleshot echoplanar MR imaging sequences: prospective study in 66 patients. Radiology 2003; 226: 7178.
27. 2weighted sequence for detection of focal liver lesions. Invest Radiol 2008;43:261266.
28. Xu PJ, Yan FH, Wang JH, Lin J, Ji Y: Added value of breathhold diffusionweighted MRI in detection of small hepatocellular carcinoma lesions compared with dynamic contrastenhanced MRI alone using receiver operating characteristic curve analysis. J MagnReson Imaging 2009;29:341349.
29. Taouli B, Chouli M, Martin AJ, Qayyum A,Coakley FV, Vilgrain V: Chronic hepatitis:role of diffusionweighted imaging and diffusion tensor imaging for the diagnosis of liver fibrosis and inflammation. J Magn Reson Imaging 2008; 28:8995.
30. Lauenstein TC, Salman K, Morreira R, et al: Gadoliniumenhanced MRI for tumor surveillance before liver transplantation: centerbased experience. Am J Roentgenol 2007;189: 663670.
31. Rode A, Bancel B, Douek P, et al: Small nodule detection in cirrhotic livers: evaluation with US, spiral CT, and MRI and correlation with pathologic examination of explanted liver. J Comput Assist Tomogr 2001;25: 327-336.
32. de Ledinghen V, Laharie D, Lecesne R, et al: Detection of nodules in liver cirrhosis: spiral computed tomography or magnetic resonance imaging? A prospective study of 88nodules in 34 patients. Eur J Gastroenterol Hepatol 2002;14:159165.
33. Stoker J, Romijn MG, de Man RA, et al: Prospective comparative study of spiral computer tomography and magnetic resonance imaging for detection of hepatocellular carcinoma. Gut 2002;51:105107.
34. Kang BK, Lim JH, Kim SH, et al: Preoperative depiction of hepatocellular carcinoma:ferumoxidesenhanced MR imaging versus triplephase helical CT. Radiology 2003;226:7985.
35. Brancatelli G, Baron RL, Peterson MS, Marsh W: Helical CT screening for hepatocellular carcinoma in patients with cirrhosis: frequency and causes of falsepositive interpretation. Am J Roentgenol 2003; 180:1007-1014.
36. Holland AE, Hecht EM, Hahn WY, et al: Importance of small (< or = 20 mm) enhancing lesions seen only during the hepatic arterial phase at MR imaging of the cirrhotic liver:evaluation and comparison with whole ex planted liver. Radiology 2005; 237: 938944.
37. Kim YK, Kim CS, Kwak HS, Lee JM: Three dimensional dynamic liver MR imaging using sensitivity encoding for detection of hepatocellular carcinomas: comparison with superparamagnetic iron oxideenhanced MR imaging. J Magn Reson Imaging 2004;20:826837.
38. Yamamoto H, Yamashita Y, Takahashi M:Development of hepatomas in hyperplastic nodules induced in the rat liver: detection with superparamagnetic iron oxideen hanced magnetic resonance imaging. Acad Radiol 1996; 3: 330335.
39. Ward J, Guthrie JA, Scott DJ, et al: Hepato cellular carcinoma in the cirrhotic liver:doublecontrast MR imaging for diagnosis. Radiology 2000;216:154162.
40. Imai Y, Murakami T, Yoshida S, et al: Super paramagnetic iron oxideenhanced magnetic resonance images of hepatocellular carcinoma: correlation with histological grading. Hepatology 2000;32: 205212.
41. Namkung S, Zech CJ, Helmberger T, Reiser MF, Schonberg SO: Superparamagnetic iron oxide (SPIO)enhanced liver MRI with feru carbotran: efficacy for characterization of focal liver lesions. J Magn Reson Imaging 2007;25: 755765.
42. Bhartia B, Ward J, Guthrie JA, Robinson PJ:Hepatocellular carcinoma in cirrhotic livers:doublecontrast thinsection MRI with pathologic correlation of explanted tissue. AJR Am J Roentgenol 2003;180:577584.
43. Kwak HS, Lee JM, Kim CS: Preoperative detection of hepatocellular carcinoma: comparison of combined contrastenhanced MRI and combined CT during arterial por tography and CT hepatic arteriography. Eur Radiol 2004;14:447457.
44. Kim YK, Kwak HS, Han YM, Kim CS: Usefulness of combining sequentially acquired gadobenate dimeglumineenhanced magnetic resonance imaging and Resovisten hanced magnetic resonance imaging for the detection of hepatocellular carcinoma: comparison with computed tomography hepatic arteriography and computed tomography arterioportography using 16slice multide tector computed tomography. J Comput Assist Tomogr 2007;31:702711.
45. Bartolozzi C, Donati F, Cioni D, Crocetti L,Lencioni R: MnDPDPenhanced MRI vs.dualphase spiral CT in the detection of he patocellular carcinoma in cirrhosis. Eur Ra diol 2000;10:16971702.
46. Kim JH, Kim MJ, Park YN, et al: Mangafo dipir trisodiumenhanced MRI of hepato cellular carcinoma: correlation with histo logical characteristics. Clin Radiol 2008;63:11951204.
47. Vogl TJ, Stupavsky A, Pegios W, et al: Hepatocellular carcinoma: evaluation with dynamic and static gadobenate dimeglumine enhanced MR imaging and histopathologic correlation. Radiology 1997;205:721728.
48. Reimer P, Schneider G, Schima W: Hepatobiliary contrast agents for contrastenhanced MRI of the liver: properties, clinical development and applications. Eur Radiol 2004; 14:559578.
49. Zech CJ, Herrmann KA, Reiser MF, Schoen berg SO: MR imaging in patients with suspected liver metastases: value of liverspecific contrast agent GdEOBDTPA. Magn Reson Med Sci 2007; 6: 4352.
50. Choi SH, Lee JM, Yu NC, et al: Hepatocellu lar carcinoma in liver transplantation candidates: detection with gadobenate dimeglu mineenhanced MRI. Am J Roentgenol2008;191: 529536.
51. Kim YK, Lee JM, Kim CS, Chung GH, Kim CY, Kim IH: Detection of liver metastases: gadobenate dimeglumineenhanced three dimensional dynamic phases and onehour delayedphase MR imaging versus super paramagnetic iron oxideenhanced MR imaging. Eur Radiol 2005; 15: 220228.
52. Kim JI, Lee JM, Choi JY, et al: The value of gadobenate dimeglumineenhanced de layedphase MR imaging for characterization of hepatocellular nodules in the cirrhotic liver. Invest Radiol 2008; 43:202210.
53. Grazioli L, Morana G, Caudana R, et al: He patocellular carcinoma: correlation between gadobenate dimeglumineenhanced MRI and pathologic findings. Invest Radiol 2000;35: 2534.
54. Tanimoto A, Kuwatsuru R, Kadoya M, et al:Evaluation of gadobenate dimeglumine in hepatocellular carcinoma: results from phase II and phase III clinical trials in Japan. J Magn Reson Imaging 1999;10: 450460.
55. Huppertz A, Balzer T, Blakeborough A, et al:Improved detection of focal liver lesions at MR imaging: multicenter comparison of gadoxetic acidenhanced MR images with intraoperative findings. Radiology 2004;230: 266275.
56. Hammerstingl R, Huppertz A, Breuer J, et al: Diagnostic efficacy of gadoxetic acid (Pri movist)enhanced MRI and spiral CT for a therapeutic strategy: comparison with intra operative and histopathologic findings in focal liver lesions. Eur Radiol 2008; 18:457-467.
57. Saito K, Kotake F, Ito N, et al: GdEOB DTPAenhanced MRI for hepatocellular carcinoma: quantitative evaluation of tumor enhancement in hepatobiliary phase. Magn Reson Med Sci 2005; 4: 19. 58 Huppertz A, Haraida S, Kraus A, et al: Enhancement of focal liver lesions at gadoxetic acidenhanced MR imaging: correlation with histopathologic findings and spiral CT initial observations. Radiology 2005;234:468478.
58. Zech CJ, Grazioli L, Breuer J, Reiser MF,Schoenberg SO: Diagnostic performance and description of morphological features of focal nodular hyperplasia in GdEOB DTPAenhanced liver magnetic resonance imaging: results of a multicenter trial. Invest Radiol 2008; 43:504511.
59. Malone D, Zech CJ, Ayuso C, Bartolozzi C, Jonas E, Tanimoto A: Magnetic resonance imaging of the liver. Consensus statement from the 1st International Primovist User Meeting. Eur Radiol 2008; 18(suppl 4):849 864.
60. Zech CJ, Vos B, Nordell A, et al: Vascular enhancement in early dynamic liver MRI in an animal model: comparison of two injection regimen and two different doses GdEOB DTPA (gadoxetic acid) with standard Gd DTPA. Inv Radiol 2009 (in press).
61. Di Martino M, Marin D, Guerrisi A, Geiger D, Galati F, Catalano C: Detection of hepato cellular carcinoma in patients with cirrhosis: intraindividual comparison of gadoxetic acid (GdEOBDTPA)enhanced MR imaging and multiphasic 64slice CT. RSNA, 2008, p 282.
62. Lee JY, Kim SH, Kim SH, Jeon YH, Lee J, Kim MJ: Ferucarbotranenhanced MRI versus gadoxetic acidenhanced MRI for the preop erative detection of hepatocellular carcinoma. RSNA, 2008, p 670.64 Lee JM, Kim SB, Lee JY, et al: Enhancement patterns on gadoxetic acidenhanced MRI of hepatocellular carcinoma in the cirrhotic liver: comparison with multiphasic liver CT. 6th International Meeting Hepatocellular Carcinoma: Eastern and Western Experiences, Seoul, 2008, p 19.
63. MartiBonmati L: MR imaging characteristics of hepatic tumors. Eur Radiol 1997; 7:249258.
64. Kanematsu M, Kondo H, Goshima S, TsugeY, Watanabe H: Magnetic resonance imaging of hepatocellular carcinoma. Oncology2008;75(suppl 1):6571.
65. Kudo M: Hepatocellular carcinoma 2009 and beyond: from the surveillance to molecular targeted therapy. Oncology 2008; 75(suppl 1):112.
66. Golfieri R, Coppola F, Fusco F, et al: Malignant progression of a small HCC nodule: hypovascular 'early HCC' converted to hyper vascular 'small HCC' within six months. DigLiver Dis 2007; 39: 883890.